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Salivary gland fine-needle aspiration (FNA) is a well-estab-
lished, minimally invasive, and cost-effective procedure that rarely 
results in complications [1,2]. FNA provides crucial information 
for clinical management of tumors, such as by distinguishing 
between neoplastic and non-neoplastic lesions and benign and 
malignant lesions, as well as by providing samples for ancillary 
tests [3-7]. Clinical management and surgical interventions 
heavily depend on the information provided by FNA, along with 
clinical data and information obtained from imaging studies. It 
is crucial to differentiate between benign and malignant lesions. 
However, intratumoral heterogeneity and overlapping cytologic 
features of different salivary gland lesions hinder accurate sub-
typing of neoplasms [8-11]. Until recently, there has been no 
uniform reporting system for salivary gland lesions. A descrip-
tive cytologic diagnosis without categorization can be confusing 
for clinicians, who require more accurate information to estab-
lish an effective management plan [9].
In an attempt to address these challenges, an international 
group of pathologists and clinicians developed a tier-based clas-
sification system with the support of the American Society of 
Cytopathology and the International Academy of Cytology that 
was designated the Milan System for Reporting Salivary Gland 
Cytopathology (MSRSGC) [12,13]. The goal of this classifica-
tion system was to standardize a reporting system for salivary 
gland lesions and to provide guidelines for their clinical man-
agement. Like other similar reporting systems, such as the 
Bethesda System for reporting thyroid cytopathology, this new 
classification system offers a clinically valuable framework for 
conceptualizing salivary gland lesions [14]. The MSRSGC is 
composed of seven categories: non-diagnostic (ND), non-neo-
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plastic (NN), atypia of undetermined significance (AUS), be-
nign neoplasm (BN), salivary gland neoplasm of uncertain ma-
lignant potential (SUMP), suspicious for malignancy (SM), and 
malignant (M).
Thus far, few studies have demonstrated promising use of 
this system. Therefore, in this study, we retrospectively applied 
the MSRSGC to categorize salivary gland FNA samples from 
2013-2018. The objective of this study was to evaluate the di-
agnostic accuracy of the MSRSGC framework and evaluate this 




A retrospective search of the cytopathology database from the 
past six years (January 2013-December 2018) for salivary gland 
(all major and minor salivary glands) FNA specimens at Gang-
nam Severance Hospital, School of Medicine, Yonsei University 
was performed. Clinical data regarding age, sex, and location of 
the lesion, as well as the type of tumor, were collected from pa-
tient medical records. Follow-up histopathological reports were 
also obtained if available. From January 2013 to December 
2018, 374 FNAs were performed, and 150 of these also under-
went surgical resection. Among them, 148 cases were finally 
enrolled in this study; two cases were excluded as they did not 
meet the inclusion criteria.
The FNAs were performed via a direct percutaneous or tran-
soral route using a 23-gauge needle. The smears were then fixed 
in 95% ethanol for Papanicolaou staining, which was performed 
in the cytopathology laboratory.
Slide review and categorization
Blinded review of all FNA slides was carried out by two pa-
thologists (J.H.P. and Y.J.C.), and each case was assigned to an 
MSRSGC category. When there was a diagnostic discrepancy, 
the two pathologists had a discussion to decide upon the best 
MSRSGC category. Category I cases were further divided into 
an inadequate group and a cyst-contents-only group. Matched 
slides of surgical specimens were also examined, and the histolog-
ical diagnoses of these surgical specimens were categorized as 
NN, BN, or M.
Evaluation of risk of malignancy and risk of neoplasm 
Cytologic-histologic correlations were performed to deter-
mine risk of malignancy (ROM) and risk of neoplasm (RON). 
The ROM was defined as the ratio between the number of 
FNAs and the number of surgically confirmed malignancies. 
Similarly, the RON was defined as the ratio between the num-
ber of FNAs and the number of neoplasms, including both be-
nign and malignant neoplasms. The ROM and RON values 
were calculated for each MSRSGC category.
RESULTS
Basal patient characteristics
This study included a total of 148 cases. The clinicopathologic 
characteristics of the patients are shown in Table 1. Our study 
population was made up of 64 (43.2%) male and 84 (56.8%) fe-
male patients, with a median age of 49 years (range, 11 to 85 
years). FNA was performed predominantly from the parotid 
gland (n = 120, 81.1%). Thirty-four cases (23.0%) were con-
firmed as M neoplasms by histological categorization. Their cat-
egorization according to the MSRSGC is shown in Fig. 1.
Correlation between pathologic diagnosis and diagnosis 
based on MSRSGC categorization of FNA results 
The preoperative cytological diagnoses and histological fol-
low-up results are listed in Table 2. There were 25 cases with 
category I FNAs: eight NN lesions, 11 BNs, and six M neoplasms. 
There were four cases of category II FNAs: two NN lesions and 
two BNs. Among the five cases with category III FNAs, three 
involved pleomorphic adenomas and the other two were one 


















Non-tumor lesion 11 (7.4)
Benign neoplasm 103 (69.6)
Malignant neoplasm 34 (23.0)
MSRSGC, Milan System for Reporting Salivary Gland Cytopathology.
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case each of metastatic breast cancer in the intraglandular lymph 
node and diffuse large B-cell lymphoma. Notably, our results 
showed that 97.5% (79/81) of category IV-A cases were BN. 
However, the FNAs of one mucoepidermoid carcinoma and one 
epithelial myoepithelial carcinoma were placed into category 
IV-A. Among the category IV-B cases, seven were BN and seven 
were M neoplasms. In contrast, all category V cases involved 
malignant tumors, half of which were epithelial myoepithelial 
carcinomas. Among the eight category VI FNA cases, seven 
involved malignant neoplasms, and one was an atypical pleo-
morphic adenoma.
Further analysis of category I cases
Of all FNA cases that were followed by surgical resection, cat-
egory I cases accounted for 17% (25/148). Of the 25 category I 
cases, 22 were located in the parotid gland, which is significantly 
higher than the remaining three cases that involved the subman-
dibular gland. The lesions diagnosed as category I in the sub-
mandibular gland included fibrocalcific nodules, IgG4-related 
disease, and chronic sialadenitis. There were six category I FNA 
cases with lesions diagnosed as malignant tumors, which includ-
ed two acinic cell carcinomas, two epithelial myoepithelial carci-
nomas, one diffuse large B-cell lymphoma, and one mucoepider-
moid carcinoma. (Fig. 1). Moreover, there were 11 category I 
FNA cases with lesions diagnosed as benign tumors, including 
four pleomorphic adenomas, four Warthin tumors, two basal 
cell adenomas, and one lipoma. Only cystic contents without 
cells were aspirated in four cases involving Warthin tumors and 
three cases involving pleomorphic adenomas (Fig. 1B).
Risk stratification and comparisons with previous studies
We found that the RON was 68.0% for ND, 50.0% for 
NN, 100% for AUS, 100% for BN, 93.3% for SUMP, 100% 
for SM, and 100% for M. The corresponding ROM values were 
24.0% for ND, 0% for NN, 40.0% for AUS, 2.5% for BN, 
46.7% for SUMP, 100% for SM, and 87.5% for M. A summary 
of the ROM values obtained in the current study and those pro-
posed by the MSRSGC and other studies is shown in Table 3. 
Discrepant cases
A discrepancy between FNA and pathological diagnoses was 
observed in six cases (Table 4). In the NN FNA group (two cas-
es), one case was diagnosed as a Warthin tumor and the other as 
a sialolipoma. Among the two cases classified as BNs using the 
Fig. 1. Distribution of malignant (A) and benign (B) neoplasms in category I fine-needle aspiration samples. PA, pleomorphic adenoma; WT, 
Warthin tumor; MEC, mucoepidermoid carcinoma; EMC, epithelial myoepithelial carcinoma; ACC, acinic cell carcinoma; DLBCL, diffuse 
large B-cell lymphoma; BCA, basal cell adenoma.
MEC (n = 1) Cystic contents (n = 3)
Cystic contents (n = 3)
Inadequate (n = 3)
Inadequate (n = 3)
DLBCL (n = 1)
ACC (n = 2)
PA (n = 3)
PA (n = 1)BCA 
(n = 1)
BCA (n = 1)Lipoma (n = 1)
EMC (n = 2)
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Non-neoplastic (n = 11) Benign neoplasm (n = 103) Malignant neoplasm (n = 34)
I (n = 25) Lymphoepithelial cyst (n = 4)
IgG4-related disease (n = 2)
Chronic sialadenitis (n = 1)
Fibrocalcific nodule (n = 1)
WT (n = 4)
PA (n = 4)
Lipoma (n = 1)
BCA (n = 2)
ACC (n = 2)
EMC (n = 2)
DLBCL (n = 1)
MEC (n = 1)
II (n = 4) Reactive lymph node (n = 1)
Epidermal cyst (n = 1)
WT (n = 1)
Sialolipoma (n = 1)
None
III (n = 5) None PA (n = 3) Metastatic carcinoma (n = 1)  
DLBCL (n = 1)
IV-A (n = 81) None PA (n = 48) 
WT (n = 27) 
Oncocytoma (n = 1) 
BCA (n = 1)
Myoepithelioma (n = 1)
Atypical PA (n = 1)
MEC (n = 1)
EMC (n = 1) 
IV-B (n = 15) Reactive lymph node (n = 1) PA (n = 4) 
Oncocytoma (n = 1) 
Myoepithelioma (n = 1)
Hemangioma (n = 1)
MEC (n = 3) 
EMC (n = 2)
ACC (n = 1)
Carcinoma ex PA (n = 1)
V (n = 10) None None MEC (n = 5)
AdCC (n = 2)
ACC (n = 1)
DLBCL (n = 1)
Sqcc (n = 1)
VI (n = 8) None Atypical PA (n = 1) MEC (n = 3)
ACC (n = 2)
Adenocarcinoma, NOS (n = 1)
Metastatic melanoma (n = 1)
WT, Warthin tumor; ACC, acinic cell carcinoma; PA, pleomorphic adenoma; EMC, epithelial myoepithelial carcinoma; DLBCL, diffuse large B-cell lymphoma; 
BCA, basal cell adenoma; MEC, mucoepidermoid carcinoma;  AdCC, adenoid cystic carcinoma; Sqcc, squamous cell carcinoma; NOS, not otherwise specified.
Fig. 2. Images of one of the false positive cases (atypical pleomorphic adenoma). (A) Fine-needle aspiration revealed highly atypical cells 
suspicious for malignant neoplasm. (B) Higher magnification of the mass showing atypical cells. (C) A lower magnification of the atypical pleo-
morphic adenoma without capsule invasion.
A B C
FNA samples, both were reported as malignant on resection 
(mucoepidermoid carcinoma and epithelial myoepithelial carci-
noma). Moreover, among the cases classified as SUMPs, one was 
later diagnosed as a reactive lymph node (paracortical hyperpla-
sia). Finally, among the cases categorized as malignant using 
FNA samples, one was diagnosed as atypical pleomorphic ade-
noma upon histological follow-up (Fig. 2). The diagnostic ac-
curacy achieved using FNA samples was 95.8% (115/120 cases) 
for the parotid gland and 96.4% (27/28 cases) for the subman-
dibular gland. Thus, the overall diagnostic accuracy using FNA 
http://jpatholtm.org/https://doi.org/10.4132/jptm.2020.06.09
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Table 3. Stratification based on risk of malignancy (%) in both current and previous studies
ND NN AUS BN SUMP SM M
ROM proposed by the MSRSGC 25.0 10.0 20.0 < 5 35.0 60.0 90.0
Current study 24.0 0 40.0 2.5 46.7 100 87.5
Rossi et al. [16] 17.0 16.0 53.0 6a 79.0 100
Song et al. [14] 17.8 14.3 30.6 2.2 46.6 78.9 98.8
Viswanathan et al. [15] 6.7 7.1 38.9 5.0 34.2 92.9 92.3
Thiryayi et al. [19] 8.5 1.6 0 1.9 26.7 100 100
Rohilla et al. [17] 0 17.4 100 7.3 50.0 - 96.0
Park et al. [18] 19.5 6.9 0 2.4 26.2 83.3 100
ND, non-diagnostic; NN, non-neoplastic; AUS, atypia of undetermined significance; BN, benign neoplasm; SUMP, salivary gland neoplasm of uncertain malig-
nant potential; SM, suspicious for malignancy; M, malignant; ROM, risk of malignancy; MSRSGC, Milan System for Reporting Salivary Gland Cytopathology.
aCases in the BN and SUMP categories were calculated together in this study.
Table 4. Cases showing a discrepancy between preoperative FNA 
diagnosis according to the MSRSGC system and the final patho-
logic diagnosis
No.




Final pathologic  
diagnosis
1 False-negative IV-A Mucoepidermoid carcinoma, low-grade
2 False-negative IV-A Epithelial myoepithelial carcinoma
3 False-negative II Warthin tumor
4 False-negative II Sialolipoma
5 False positive VI Atypical pleomorphic adenoma
6 False positive IV-B Reactive lymph node
FNA, fine-needle aspiration; MSRSGC, Milan System for Reporting Salivary 
Gland Cytopathology.
samples was 95.9% (142/148 cases).
DISCUSSION
In this study, we reclassified FNA cases from a single center 
using the MSRSGC and correlated the results with those ob-
tained using pathological diagnoses. Most salivary gland FNA 
cases that completed surgical follow-up were benign (103 cases; 
69.6%), which is similar to the incidence reported by other 
studies [14-17]. The diagnosis rate of ND at our institution was 
23.5%, with 68.0% RON and 24.0% ROM. Notably, the fre-
quency of ND diagnosis was higher than the 10% frequency set 
by the MSRSGC.
The ROM of ND in our study was high compared to that of 
other studies [14-19]. Many factors are involved in an ND diag-
nosis, including aspiration technique, character of the lesion, 
method of specimen processing, and presence of artifacts from 
slide preparation [20]. Previous studies have suggested that rare, 
highly atypical cells could be placed in a category V if there is 
enough clinical suspicion, even if the number of cells to support 
this classification is insufficient [20].
In this study, we divided category I cases into subtypes and 
examined their characteristics. Interestingly, 12.5% (4/32) of all 
Warthin tumors were placed in category I, and all four of these 
cases had only cystic contents. It is presumed that Warthin tumors 
could be accompanied by cystic degenerative changes in the cen-
ter of the lesion. When category I was divided into two subtypes 
(inadequate and cystic contents only), there were no significant 
differences between the ROM values of the two subtypes (25% 
and 23.1%, respectively).
The ROM values for the NN and BN categories in our study 
were 0% and 2.5%, respectively, while the RON values were 
50.0% and 100%. The ROM values for the NN and BN catego-
ries were lower than the proposed ROM incidence of 10% and 
lower than the 5% ROM proposed by the MSRSGC. In compar-
ison, the ROM values for the NN and BN categories in other 
studies ranged from 1.6%-17.4% and from 1.9%-7.3%, respec-
tively (Table 3) [14-19]. In our study, Warthin tumors and sialo-
lipoma cases were reported in the NN category, which is in con-
trast to the findings of studies by Rossi et al. [16], Viswanathan 
et al. [15], and Song et al. [14], in which B-cell lymphomas pre-
dominantly accounted for false-negative diagnoses. The increase 
in ROM in the BN category in our study was attributed to one 
case of low-grade mucoepidermoid carcinoma and one case of epi-
thelial myoepithelial carcinoma, which exhibited a similar distri-
bution to that observed in the study by Rossi et al. [16]. More-
over, in the study by Song et al., the increase in ROM in the BN 
category was attributed to three cases of carcinoma ex pleomor-
phic adenoma and one case of adenoid cystic carcinoma [14].
According to the MSRSGC guidelines, cases in the AUS cat-
egory should not exceed 10% of the total cases examined. In 
the current study, 3.8% of salivary gland FNAs were catego-
rized as AUS, which is in accordance with this recommenda-
tion. The ROM for the AUS category was 40%, which is higher 
than the 20% proposed by the MSRSGC. However, one limita-
tion of our study was that only five AUS FNAs were included, 
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2020.06.09
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precluding precise analysis of ROM for this type. In compari-
son, other studies have reported an ROM ranging from 
0-100%. Moreover, various entities were included in this cate-
gory, with pleomorphic adenoma being the most common.
The RON and ROM values for the SUMP category in our 
study were 93.3% and 46.7%, respectively, with pleomorphic 
adenoma and mucoepidermoid carcinoma being the most com-
mon benign and malignant diagnoses, respectively. The ROM 
was higher than the MSRSGC target rate and was similar to 
those reported in other studies (Song et al. [14] and Viswana-
than et al. [15] reported ROMs of 46.6% and 34.2%, respec-
tively). For the SM category, the RON and ROM values were 
100% and 100%, respectively. Notably, the reported ROM for 
this category varies from institution to institution, ranging from 
78.9%-100% [14-19]. This outcome is likely due to different 
institutional practices and disease populations, as well as differ-
ences in pathologist experience. Thus, this finding may repre-
sent a limitation of single-center studies. The RON and ROM 
values for the M category were 100% and 87.5%, respectively. 
The ROM in our study was slightly lower compared to that in 
the MSRSGC and other published studies [14-19]. In previous 
studies, squamous cell carcinoma was the most common malig-
nant tumor in the M category [14-16]. However, the M category 
in our study consisted of only one case with squamous cell carci-
noma; instead, mucoepidermoid carcinoma was the most fre-
quently diagnosed malignancy. Compared to other studies, the 
limited sample size (eight cases) in our study may have led to both 
a lower ROM and greater differences in tumor type [14-19].
In this study, there were four false-negative and two false 
positive cases. Contributing factors might have included sam-
pling errors, inadequacy of technique, vagueness in interpreta-
tion, and underestimation of low-grade malignant tumors. In 
particular, mucoepidermoid carcinomas with cystic changes are 
difficult to diagnose due to a high incidence of failure to gain 
optimal material [21,22]. A limited number of mucoepider-
moid carcinoma cases contains all three cell types (mucous, in-
termediate, and squamous cells) [23]. However, among malig-
nant tumors, mucoepidermoid carcinoma could often be 
relatively straightforwardly assigned to the SM category when 
mucus cells are present. One of the false positive cases in the 
present study involved an atypical pleomorphic adenoma; the 
FNA specimen showed several clusters composed of markedly 
atypical cells in the degenerated background (Fig. 2). In the re-
sected specimens, except for focal cytologic atypia, there were 
no features that indicated malignancy. Rohilla et al. [17] re-
ported a similar false-positive case. Given this intriguing case, 
careful consideration of both the radiological findings and clini-
cal assessments may help improve the predictive power of the 
MSRSGC.
In conclusion, we confirmed that the ROM at our institute was 
similar to the proposed ROM. Thus, the MSRSGC appeared to 
be effective in facilitating communication between pathologists 
and clinicians and may lead to a more comprehensive understand-
ing of cytological diagnoses and establishment of appropriate 
treatment strategies.
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